Page last updated: 2024-08-26

arsenic and B-Cell Lymphoma

arsenic has been researched along with B-Cell Lymphoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goel, A; Spitz, DR; Weiner, GJ1
Giri, U; Kala, SV; Lieberman, MW; Story, MD; Terry, NH1
Chen, L; Chen, SY; Li, QY; Xu, XP; Xu, XW; Yi, K; Zhou, F1
Duan, Y; Li, HM; Liu, H; Yu, MJ; Zhang, XM1
Au, WY; Fong, BM; Kwong, YL; Tam, S; Wan, TS; Yip, SF1
Arora, M; Kaul, D; Sharma, M; Sharma, S1
Ganapathy, S; Ha, CS; Li, X; Su, H; Yuan, ZM1

Reviews

1 review(s) available for arsenic and B-Cell Lymphoma

ArticleYear
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy

2012

Other Studies

6 other study(ies) available for arsenic and B-Cell Lymphoma

ArticleYear
Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Glutathione Transferase; Humans; Lymphoma, B-Cell; Membrane Potentials; Mice; Mitochondria; Oxides

2005
[Effects of dexamethasone on arsenic trioxide induced apoptosis, NF-kappaB activation and gene expression in lymphoma cell line].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2005, Volume: 26, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dexamethasone; Drug Interactions; Glucocorticoids; Humans; Immunohistochemistry; Lymphoma, B-Cell; Matrix Metalloproteinase 9; NF-kappa B; Oxides; Vascular Endothelial Growth Factor A

2005
[Inhibited proliferation of B-lymphoma Raji cells and down-regulated expression of VEGF by arsenic trioxide].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Down-Regulation; Humans; Lymphoma, B-Cell; Oxides; RNA, Messenger; Vascular Endothelial Growth Factor A

2006
Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
    Leukemia research, 2009, Volume: 33, Issue:1

    Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Male; Neoplasms, Second Primary; Oxides

2009
Regulation of cellular Cyclin D1 gene by arsenic is mediated through miR-2909.
    Gene, 2013, Jun-10, Volume: 522, Issue:1

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic; B-Cell Lymphoma 3 Protein; Cell Line, Tumor; Cell Transformation, Neoplastic; Deubiquitinating Enzyme CYLD; Genes, bcl-1; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Lymphoma, B-Cell; MicroRNAs; Protein Biosynthesis; Proto-Oncogene Proteins; Repressor Proteins; Sp1 Transcription Factor; Transcription Factors; Tumor Suppressor Proteins

2013
p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.
    International journal of radiation oncology, biology, physics, 2015, Aug-01, Volume: 92, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arsenic; Biomarkers; Bone Marrow; Bone Marrow Cells; DNA Damage; Female; Genes, p53; Glucose Transporter Type 1; Glucose Transporter Type 3; Heterografts; Histones; In Situ Nick-End Labeling; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Radiation Dosage; Radiation Injuries, Experimental; Radiation Tolerance; Radiation-Protective Agents; Radioimmunotherapy; Transcriptional Activation; Yttrium Radioisotopes

2015